Navigation Links
Transcept Pharmaceuticals Appoints Key Senior Executives
Date:7/2/2008

cutives with extensive experience in both pharmaceutical development and commercialization," said Ms. Koppy. "I look forward to leading the Transcept effort to build partner relationships and to license development programs."

About Intermezzo(R)

Transcept Pharmaceuticals' lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge) employs the company's proprietary Bimucoral(R) technology in a mint-flavored, sublingual lozenge formulated to dissolve under the tongue in approximately two minutes. This novel pH modification delivery system has been shown to accelerate the bioavailability of zolpidem, despite the substantially lower Intermezzo(R) dose vs. the doses employed with previously available forms of this active agent.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the Company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc. The Ruth Group

Michael Gill Investors / Media

Director of Communications Stephanie Carrington
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 ... ), a leader in synthetic biology, today announced it ... Fruits (OSF), the pioneering agricultural company behind the ... non-browning apple. Through the acquisition, Intrexon expands its food ... appetizing and convenient for consumers while providing economic benefit ...
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine”) (TSX: IMV), ... announced that the U.S. Food and Drug Administration ... and Phase I clinical trials of the DPX-Anthrax ... co-development agreement signed with Gilead Life Sciences. The ... the DPX-Survivac. , “We have been in talks ...
(Date:2/27/2015)... February 27, 2015 FamilyFarms Group is ... Manager of State Line Farms, received the 2015 Tomorrow’s ... producer, under the age of 35, who has demonstrated ... an honor to win the Tomorrow's Top Producer Horizon ... won the Top Producer Award and learning from their ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
... Boston Scientific Corporation (NYSE: BSX ) ... ® Clinical Science program, which demonstrated that defibrillator ... in mortality due to defibrillator shock.  Instead, the authors ... is not attributed to the defibrillator shock itself, but ...
... May 5, 2011 Momentum is building ... (ErgoExpo), the largest ergonomics event in the nation, held ... 2, 2011. The expo has already grown over 10% ... and exhibitors increasing the size of their exhibit space. ...
... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... commercialization of products for central nervous system disorders, today ... ended March 31, 2011. "We are very ... date in 2011," said Mihael H. Polymeropoulos, M.D., President ...
Cached Biology Technology:ALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock 2ALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock 3ALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock 42011 National Ergonomics Conference and Expo (ErgoExpo) Announces HP, CDC, VPPPA Leaders to Keynote; Expo on Pace to Sell Out 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 3Vanda Pharmaceuticals Reports First Quarter 2011 Results 4Vanda Pharmaceuticals Reports First Quarter 2011 Results 5Vanda Pharmaceuticals Reports First Quarter 2011 Results 6Vanda Pharmaceuticals Reports First Quarter 2011 Results 7Vanda Pharmaceuticals Reports First Quarter 2011 Results 8
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... WASHINGTON (20 April 2010) -- Ultrasound pioneer Gerald J. ... the highest award in the engineering profession on ... (AAES). Posakony,s pioneering contributions to the fields ... were recognized during AAES, 31st annual awards ceremony at ...
... today new study results showing that when and how ... life has vital implications to a child,s developmental, diagnostic, ... Journal of Autism and Developmental Disorders (Epub ahead ... warning signs may actually be at lower risk for ...
... Researchers have made an important breakthrough in the use of ... cells an innovative technology that could significantly reduce the ... The advance was just reported in Current Applied Physics ... and Yeungnam University in Korea. This is one of ...
Cached Biology News:Ultrasound pioneer receives highest award in engineering profession 2Ultrasound pioneer receives highest award in engineering profession 3Ultrasound pioneer receives highest award in engineering profession 4Ultrasound pioneer receives highest award in engineering profession 5Ultrasound pioneer receives highest award in engineering profession 6Study provides new insights into the implications of autism onset patterns 2Study provides new insights into the implications of autism onset patterns 3Advance made in thin-film solar cell technology 2Advance made in thin-film solar cell technology 3
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
...
Biology Products: